Sarda Proteins Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve Sarda Proteins Ltd has informed ....
Awaiting price reaction for this filing.
Sarda Proteins Ltd has informed BSE that its Board of Directors will meet on Friday, 14th November 2025 at the registered office. The main agenda is to consider and approve the Standalone Un-Audited Financial Results for the quarter ended 30th September 2025 (Q2 FY26). This is a routine compliance filing under SEBI LODR Regulation 29, ahead of the actual results announcement. The company also noted that the trading window for dealing in its securities has been closed since 1st October 2025 and will reopen 48 hours after the results are declared. The intimation is signed by Director Khilan Savaliya (DIN: 08790209). No actual financial numbers were disclosed in this filing.
This is a standard pre-results intimation with no direct impact on the stock price. Retail investors should monitor the company's announcement on or after 14th November for the actual Q2 performance, which could influence short-term price movement.